Therapeutic use of cpg oligodeoxynucleotide for skin disease

• US 20090062224A1
• Filed: 11/04/2005
• Published: 03/05/2009
• Est. Priority Date: 11/05/2004
• Status: Active Grant

• Current Assignee: Bio Clue And Solution Co Ltd., Dong-Heon Shin, Tae-Yoon Kim
• Original Assignee: Bio Clue And Solution Co Ltd., Dong-Heon Shin, Tae-Yoon Kim
• Inventors: Kwon, Hyung-Joo, Kim, Tae-Yoon, Kim, Doo-Sik, Kim, Yang-Soon
• Granted Patent: US 7,935,678 B2
• Time in Patent Office: Days
• US Class Current: 514/44.R
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 31/7125 Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14

Abstract

Disclosed is the therapeutic use of CpG oligodeoxynucleotides for skin diseases. The CpG oligodeoxynucleotides (CpG ODNs) of the present invention show excellent immunoactive effects against skin diseases in both cases of CpG ODNs with a phosphorothioate backbone and CpG ODNs with a phosphodiester backbone.

Claims

1. A method for inhibiting a Th2 cytokine and/or inducing a Th1 cytokine, comprising administering to a subject in need thereof an effective amount of a CpG oligodeoxynucleotide represented by the following formula:

[formula] SYYSSACGTTSNYRAWMYTC (SEQ ID NO.

     1)

wherein, S is G or C;

Y is C or T;

N is any one selected from the group consisting of A, G, T and C;

R is G or A;

W is A or T; and

M is A or C, and wherein the CpG oligodeoxynucleotide comprises at least two unmethylated CpG motifs.

2. The method according to claim 1, wherein the Th2 cytokine is IL-4 or IL-10.

3. The method according to claim 1, wherein the Th1 cytokine is IL-12 or IFN-γ

.

4. The method according to claim 1, wherein the YS or YR dinucleotide in the formula is CG.

5. The method according to claim 1, wherein the CpG oligodeoxynucleotide has any one nucleotide sequence selected from the group consisting of SEQ ID NOs. 2-8.

6. The method according to claim 1, wherein the CpG oligodeoxynucleotide has a phosphodiester or phosphorothioate backbone.

7. A method for stimulating an immune response, comprising administering to a subject in need thereof an effective amount of a CpG oligodeoxynucleotide represented by the following formula:

[formula] SYYSSACGTTSNYRAWMYTC (SEQ ID NO.

     1)

wherein S is G or C;

Y is C or T;

N is any one selected from the group consisting of A, G, T and C;

R is G or A;

W is A or T; and

M is A or C, and wherein the CpG oligodeoxynucleotide comprises at least two unmethylated CpG motifs.

8. The method according to claim 7, wherein the YS or YR dinucleotide in the formula is CG.

9. The method according to claim 7, wherein the CpG oligodeoxynucleotide has any one nucleotide sequence selected from the group consisting of SEQ ID NOs. 2-8.

10. The method according to claim 7, wherein the CpG oligodeoxynucleotide has a phosphodiester or phosphorothioate backbone.

11. A method for treating or preventing a skin disease, comprising administering to a subject in need thereof an effective amount of a CpG oligodeoxynucleotide represented by the following formula:

[formula] SYYSSACGTTSNYRAWMYTC (SEQ ID NO.

     1)

wherein S is G or C;

Y is C or T;

N is any one selected from the group consisting of A, G, T and C;

R is G or A;

W is A or T; and

M is A or C, and wherein the CpG oligodeoxynucleotide comprises at least two unmethylated CpG motifs.

12. The method according to claim 11, wherein the YS or YR dinucleotide in the above formula is CG.

13. The method according to claim 11, wherein the CpG oligodeoxynucleotide has any one nucleotide sequence selected from the group consisting of SEQ ID NOs. 2-8.

14. The method according to claim 11, wherein the CpG oligodeoxynucleotide has a phosphodiester or phosphorothioate backbone.

15. The method according to claim 11, wherein the skin disease is selected from the group consisting of atopic dermatitis, allergic skin disease, viral skin disease and skin cancer.

16. A composition for treating or preventing a skin disease, comprising a CpG oligodeoxynucleotide represented by the following formula, as an active ingredient:

[formula] SYYSSACGTTSNYRAWMYTC (SEQ ID NO.

     1)

wherein S is G or C;

Y is C or T;

N is any one selected from the group consisting of A, G, T and C;

R is G or A;

W is A or T; and

M is A or C, and wherein the CpG oligodeoxynucleotide comprises at least two unmethylated CpG motifs.

17. A composition for stimulating an immune response, comprising a CpG oligodeoxynucleotide represented by the following formula, as an active ingredient:

[formula] SYYSSACGTTSNYRAWMYTC (SEQ ID NO.

     1)

wherein S is G or C;

Y is C or T;

N is any one selected from the group consisting of A, G, T and C;

R is G or A;

W is A or T; and

M is A or C, and wherein the CpG oligodeoxynucleotide comprises at least two unmethylated CpG motifs.

18. Use of a CpG oligodeoxynucleotide represented by the following formula for the preparation of an agent for treating or preventing a skin disease:

[formula] SYYSSACGTTSNYRAWMYTC (SEQ ID NO.

     1)

wherein S is G or C;

Y is C or T;

N is any one selected from the group consisting of A, G, T and C;

R is G or A;

W is A or T; and

M is A or C, and wherein the CpG oligodeoxynucleotide comprises at least two unmethylated CpG motifs.

19. Use of a CpG oligodeoxynucleotide represented by the following formula for the preparation of an agent for stimulating an immune response:

[formula] SYYSSACGTTSNYRAWMYTC (SEQ ID NO.

     1)

wherein S is G or C;

Y is C or T;

N is any one selected from the group consisting of A, G, T and C;

R is G or A;

W is A or T; and

M is A or C, and wherein the CpG oligodeoxynucleotide comprises at least two unmethylated CpG motifs.